Doxirobe

RSS

Doxycycline

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Doxirobe has not been renewed by the marketing authorisation holder and is now withdrawn.

This EPAR was last updated on 16/09/2004

Authorisation details

Product details
Name
Doxirobe
Agency product number
EMEA/V/C/000044
Active substance
doxycycline
International non-proprietary name (INN) or common name
Doxycycline
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QJ01AA02
Publication details
Marketing-authorisation holder
Pfizer Limited
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
16/09/1999
Contact address
Ramsgate Road
Sandwich
Kent
CT13 9NJ
United Kingdom

Product information

01/12/2003 Doxirobe - EMEA/V/C/000044 -

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Treatment of periodontal disease in dogs.
Periodontal pocket probing depths >=4 mm are evidence of disease that may be responsive to treatment with the Doxirobe Gel. Use of this product as directed should result in attachment level gains, periodontal pocket depth reductions, local antimicrobial effect and improved gingival health. Noticeable improvements in these parameters should be evident within 2-4 weeks following treatment. The response in individual dogs is dependent on the severity of the condition and rigor of adjunctive therapy.

How useful was this page?

Add your rating